PE, VC investments in April touch USD 2.4 billion on large deals: EY

Published On 2018-05-20 04:15 GMT   |   Update On 2018-05-20 04:15 GMT




New Delhi: Private equity and venture capital investments in April were up 23 percent at USD 2.4 billion, backed by large deals in sectors like e-commerce and life sciences, says an EY report.

According to EY, there were 69 PE/VC deals in April worth USD 2,370.09 million, while the corresponding month of 2017 had registered 66 such deals worth USD 1,920.32 million.

"PE/VC deal activity in India continues to gather steam and become more robust. Both investments, as well as exits, are on an upward trend," said Vivek Soni, Partner, and Leader for Private Equity Advisory, EY.

Exits also recorded a significant growth of 47 percent in terms of value during the same period, primarily on account of a single large exit by Actis worth USD 692 million.

Soni said the recently announced majority acquisition of Flipkart by Walmart is expected to re-rate the Indian startup sector.

"We believe it will inject new found enthusiasm and energy into the early to mid-stage investing eco-system and inspire many more entrepreneurs," he said.

The next 4-5 years are expected to be the golden age for the Indian PE/VC sector, provided there is stability in the political as well as policy front, he said.

The largest investment in April 2018 saw Softbank invest USD 400 million for a 21 percent stake in Paytm Mall.

This was followed by couple of deals in the life sciences sector - USD 350 million investment in Mankind Pharma by ChrysCapital GIC and CPPIB for a 10 percent stake, and Apax Partner's USD 350 million acquisition of Healthium Medtech, a maker of the surgical equipment.




Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News